The results of a comparative efficacy study of Flublok Quadrivalent will be announced in June, according to the Protein Sciences Corporation.
Protein Sciences Corporation announced today that results from a double-blinded comparative efficacy study of Flublok Quadrivalent in adults over 50 are expected in June. The study is designed to demonstrate whether Flublok’s higher antigen content and its modern production process that avoids the introduction of egg-based mutations into the vaccine’s active ingredients will result in better efficacy than the recently announced flu vaccine efficacy of 14% in adults older than 50.
